To identify potential therapeutic avenues for CS1 and CS3 tumors, we employed transcriptome-based drug response modeling, which revealed selective sensitivity to compounds including HSP90 and MEK inhibitors—agents known to counteract immune resistance by modulating tumor-intrinsic signaling and restoring immune susceptibility. Here, MAP2K7 is linked to neoplasm.